CERO Therapeutics Holdings, Inc. announced on April 30, 2025, that TriStar Centennial Medical Center, through Sarah Cannon Research Institute (SCRI), in Nashville, Tennessee, has been designated as a clinical trial site for the company’s Phase 1 clinical trial of CER-1236. This trial is focused on patients with acute myeloid leukemia (AML).
Patient enrollment for the trial is underway, with the first patient expected to be dosed during the first half of 2025. TriStar Centennial Medical Center, collaborating with SCRI, offers innovative clinical research trials for various disease indications, contributing to the trial's reach.
Stephen Strickland, Jr., M.D., MSCI, Director of Leukemia Research for SCRI, noted that preclinical studies demonstrated CER-1236's multifunctional approach to killing cancer cells without harming healthy cells. CEO Chris Ehrlich highlighted the rapid uptake of clinical trial site partners as a testament to the scientific work and the dedication of the teams involved.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.